One attractive paradigm of anticancer strategies is to target oncogenes for sensitization of tumor cells to apoptosis. The rationale is that onco-proteins rely on other factors to maintain homeostasis or promote cancer cell survival. Disruption of one of coordinating proteins would trigger an apoptotic crisis in cancer cells. Oncogenic Ras has been discovered in about 30-40% of human cancers. However, inhibitors targeting mutated Ras have proved not to be effective clinically. Recently, the focus has been on finding signaling pathways that are downstream of or parallel with Ras, and are essential for cancer cells to survive. In the effort to identify the apoptotic partners of mutated Ras, studies showed that loss of PKC, together with mutated Ras, are synthetically lethal in many types of tumors. Recently, we made the novel observation that loss of different PKC isoforms differentially sensitized cells expressing mutated ras to apoptosis. In particular, we identified that co-suppression of PKC?/? were critical for the induction of apoptosis in cancer cells harboring mutated ras, in which PI3K/Akt function downstream of Ras to mobilized two signaling pathways: one was via upregulating ROS and ER stress-mediated UPR for switching on the apoptotic machinery;and another one was through activating PKC?, resulting in p73 phosphorylation and PUMA/NOXA upregulation. In this renewal application, we will investigate the molecular mechanisms of our novel observation of how Ras, upon loss of PKC??/?, differentially utilizes its downstream effector pathways to selectively sensitize tumor cells to apoptosis, with less or no toxicity to normal cells or surrounding tissues. We will determine how ROS and PKC??/p73 pathways are being redirected by aberrant Ras/PI3K/Akt to activate cell death program after co-suppression of PKC??/?. Thus, the hypothesis to be tested is that upon co-knockdown of PKC??/?, PI3K/Akt are key players in the induction of Ras-mediated apoptosis, which is via perturbing redox homeostasis as well as through activating PKC??/ p73-mediated apoptotic network. Accordingly, 4 Specific Aims are formed.
Aim 1 will study the mechanisms by which ROS is upregulated in cells expressing aberrant ras or PI3K/Akt upon co- suppression of PKC??/?.
Aim 2 will determine the mechanisms by which ROS induces ER-stress/UPR activation in cells expressing aberrant ras or PI3K/Akt upon co-suppression of PKC??/?.
In Aim 3, we will determine the role of p73 in the sensitization of cells expressing aberrant ras or PI3K/Akt to apoptosis after co- knockdown of PKC??/?.
In Aim 4, we will determine the pro-apoptotic effect in cells expressing aberrant ras or PI3K/Akt in vitro and in vivo after co-suppression of PKC??/?. The outcomes of our research will reveal molecules involved in this synthetic lethal interaction between Ras mutations and loss of PKC??/?, which will provide the potential information for designing more effective drugs to treat human cancers harboring aberrant ras or PI3K/Akt.

Public Health Relevance

Mutations in oncogenes are common in human tumors. Activating mutations in the ras oncogenes contribute to the formation of more than 30% of human malignancies. Attempts to target mutated Ras with chemical inhibitors have not been successful. Recently, there has been increasing attentions in finding and targeting signaling pathways that function downstream of or parallel with Ras. We discovered the synthetic lethal interaction between aberrant Ras and loss of PKC??/?. The proposal aims at the elucidation of the underlying mechanisms by which PI3K/Akt functions downstream of Ras upon co-suppression of PKC??/? to induce apoptosis via activating p73/PUMA/NOXA signaling as well as NADPH/ROS/UPR pathway. The outcomes of our proposal may provide new strategies for the treatment with cancer harboring aberrant Ras or PI3K/Akt.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100498-07
Application #
8664349
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Salnikow, Konstantin
Project Start
2003-02-01
Project End
2018-04-30
Budget Start
2014-05-23
Budget End
2015-04-30
Support Year
7
Fiscal Year
2014
Total Cost
$234,552
Indirect Cost
$83,715
Name
Northeastern University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Nishioka, T; Luo, L-Y; Shen, L et al. (2014) Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 110:1785-92
Zhu, Tongbo; Chen, Lihua; Du, Wei et al. (2010) Synthetic Lethality Induced by Loss of PKC ýý and Mutated Ras. Genes Cancer 1:142-151
Guo, Jinjin; Zhu, Tongbo; Chen, Lihua et al. (2010) Differential Sensitization of Different Prostate Cancer Cells to Apoptosis. Genes Cancer 1:836-846
Reiterer, Gudrun; Chen, Lihua; Tassef, Ryan et al. (2010) RAF associates with phosphorylated nuclear BubR1 during endoreduplication induced by JAK inhibition. Cell Cycle 9:3297-304
Ahn, Quein; Jeong, Soo-Jin; Lee, Hyo-Jung et al. (2010) Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett 298:212-21
Zhu, T; Tsuji, T; Chen, C (2010) Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras. Oncogene 29:1050-61
Guo, Jinjin; Zhu, Tongbo; Luo, Ling-Yu et al. (2009) PI3K Acts in synergy with loss of PKC to elicit apoptosis via the UPR. J Cell Biochem 107:76-85
Guo, Jinjin; Zhu, Tongbo; Xiao, Zhi-Xiong J et al. (2007) Modulation of intracellular signaling pathways to induce apoptosis in prostate cancer cells. J Biol Chem 282:24364-72
Zhu, T; Guo, J; Collins, L et al. (2007) Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells. Br J Cancer 96:583-90
Guo, Jinjin; Zhu, Tongbo; Collins, Leaann et al. (2007) Modulation of lung cancer growth arrest and apoptosis by Phellinus Linteus. Mol Carcinog 46:144-54

Showing the most recent 10 out of 12 publications